Warning: The NCBI web site requires JavaScript to function. more...

My NCBI Sign In

Result Filters

Br J Cancer. 2005 Nov 28;93(11):1257-66.

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1.

Pericleous LM, Richards J, Epenetos AA, Courtenay-Luck N, Deonarain MP.

Source

Department of Biological Sciences, Imperial College London, UK.

Abstract

The humanised HMFG-1 immunoglobulin has been extensively developed as a clinical immunotherapeutic agent for MUC1 expressing tumours. We have constructed a single-chain Fv (scFv) and Fab fragment from this antibody and shown that both these species retain their specificity for MUC1. The scFv was less stable and less soluble than the Fab. Detailed analyses of the binding kinetics of the whole IgG and Fab fragment show that the affinity for MUC1 synthetic peptides is low (approximately 100 nM for the IgG and 10 muM for the Fab), with particularly low but similar dissociation rate constants (0.031-0.095 s(-1)). Binding to native antigen on the cell surface is over two orders of magnitude better. Confocal immunofluorescence microscopy shows that both the IgG and Fab are internalised rapidly (the IgG is internalised within 15 min) and colocalise to early endosomes. This work provides an appreciation of the binding, internalising and trafficking kinetics, important for the development of future therapeutics based on this antibody.

PMID:: 16265351; [PubMed - indexed for MEDLINE]
PMCID:: PMC3216111

Free PMC Article

Images from this publication.See all images (7) Free text

Publication Types, MeSH Terms, Substances

Publication Types

Research Support, Non-U.S. Gov't

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Libraries

LinkOut Holdings

Supplemental Content

Icon for Nature Publishing Group

Icon for PubMed Central

Save items

loading

Related citations in PubMed

Characterisation of a recombinant Fv fragment of anti-MUC1 antibody HMFG1. [Cancer Lett. 1994]
Characterisation of a recombinant Fv fragment of anti-MUC1 antibody HMFG1.
Davies GM, Bösze S, Hudecz F, Price MR, Tendler SJ. Cancer Lett. 1994 Jul 29; 82(2):179-84.
Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. [Cancer Res. 1998]
Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P, Kandilogiannaki M, Petrarca C, von Mensdorff-Pouilly S, Hilgers JH, Krambovitis E, Arends JW, Hoogenboom HR. Cancer Res. 1998 Oct 1; 58(19):4324-32.
A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. [Am J Pathol. 2002]
A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized.
Henderikx P, Coolen-van Neer N, Jacobs A, van der Linden E, Arends JW, Müllberg J, Hoogenboom HR. Am J Pathol. 2002 May; 160(5):1597-608.
Review Pharmacokinetics and biodistribution of genetically-engineered antibodies. [Q J Nucl Med. 1998]
Review Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Q J Nucl Med. 1998 Dec; 42(4):225-41.
Review Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers. [Q J Nucl Med Mol Imaging. 2007]
Review Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers.
Albrecht H, Denardo GL, Denardo SJ. Q J Nucl Med Mol Imaging. 2007 Dec; 51(4):304-13. Epub 2007 May 1.

See reviews... See all...

Cited by 3 PubMed Central articles

Rise and fall of an anti-MUC1 specific antibody. [PLoS One. 2011]
Rise and fall of an anti-MUC1 specific antibody.
Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B, Fournier N, et al. PLoS One. 2011 Jan 14; 6(1):e15921. Epub 2011 Jan 14.
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. [Br J Cancer. 2010]
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.
Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X. Br J Cancer. 2010 Mar 2; 102(5):827-32. Epub 2010 Feb 16.
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. [Breast Cancer Res. 2009]
Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.
Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N. Breast Cancer Res. 2009; 11(5):R73.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies ...
Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1.
Br J Cancer. 2005 Nov 28 ;93(11):1257-66.

PubMed
Reduction in apoptosis relative to mitosis in histologically normal epithelium a...
Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast.
J Pathol. 1992 May ;167(1):25-32.

PubMed
Prolonged survival of patients receiving trastuzumab beyond disease progression ...
Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC).
Onkologie. 2005 Nov ;28(11):582-6.

PubMed
Breast cancer (1)
Breast cancer (1)
N Engl J Med. 1992 Jul 30 ;327(5):319-28.

PubMed
Interleukin-17 receptor deficiency results in impaired synovial expression of in...
Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis.
Arthritis Rheum. 2005 Oct ;52(10):3239-47.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

You are here: NCBI > Literature > PubMed

Write to the Help Desk